Andrew J Lee

List of Publications by Year
in descending order

		201674	289244
45 papers	7,413 citations	27 h-index	40 g-index
50 all docs	50 docs citations	50 times ranked	10520 citing authors

#	Article	IF	Citations
1	Association analysis identifies 65 new breast cancer risk loci. Nature, 2017, 551, 92-94.	27.8	1,099
2	Large-scale genotyping identifies 41 new loci associated with breast cancer risk. Nature Genetics, 2013, 45, 353-361.	21.4	960
3	Breast-Cancer Risk in Families with Mutations in *PALB2*. New England Journal of Medicine, 2014, 371, 497-506.	27.0	745
4	Polygenic Risk Scores for Prediction of Breast Cancer and Breast Cancer Subtypes. American Journal of Human Genetics, 2019, 104, 21-34.	6.2	711
5	BOADICEA: a comprehensive breast cancer risk prediction model incorporating genetic and nongenetic risk factors. Genetics in Medicine, 2019, 21, 1708-1718.	2.4	415
6	Identification of 12 new susceptibility loci for different histotypes of epithelial ovarian cancer. Nature Genetics, 2017, 49, 680-691.	21.4	356
7	Prevalence and Penetrance of Major Genes and Polygenes for Colorectal Cancer. Cancer Epidemiology Biomarkers and Prevention, 2017, 26, 404-412.	2.5	341
8	Identification of ten variants associated with risk of estrogen-receptor-negative breast cancer. Nature Genetics, 2017, 49, 1767-1778.	21.4	289
9	The OncoArray Consortium: A Network for Understanding the Genetic Architecture of Common Cancers. Cancer Epidemiology Biomarkers and Prevention, 2017, 26, 126-135.	2.5	278
10	Cancer Risks Associated With Germline *PALB2* Pathogenic Variants: An International Study of 524 Families. Journal of Clinical Oncology, 2020, 38, 674-685.	1.6	270
11	Evaluation of Polygenic Risk Scores for Breast and Ovarian Cancer Risk Prediction in BRCA1 and BRCA2 Mutation Carriers. Journal of the National Cancer Institute, 2017, 109, .	6.3	242
12	Identification of six new susceptibility loci for invasive epithelial ovarian cancer. Nature Genetics, 2015, 47, 164-171.	21.4	221
13	Age- and Tumor Subtype–Specific Breast Cancer Risk Estimates for *CHEK2**1100delC Carriers. Journal of Clinical Oncology, 2016, 34, 2750-2760.	1.6	152
14	Prediction of Breast and Prostate Cancer Risks in Male *BRCA1* and *BRCA2* Mutation Carriers Using Polygenic Risk Scores. Journal of Clinical Oncology, 2017, 35, 2240-2250.	1.6	152
15	Cost-effectiveness of Population-Based BRCA1, BRCA2, RAD51C, RAD51D, BRIP1, PALB2 Mutation Testing in Unselected General Population Women. Journal of the National Cancer Institute, 2018, 110, 714-725.	6.3	138
16	Breast cancer risk variants at 6q25 display different phenotype associations and regulate ESR1, RMND1 and CCDC170. Nature Genetics, 2016, 48, 374-386.	21.4	125
17	Ovarian and Breast Cancer Risks Associated With Pathogenic Variants in *RAD51C* and *RAD51D*. Journal of the National Cancer Institute, 2020, 112, 1242-1250.	6.3	106
18	CanRisk Tool—A Web Interface for the Prediction of Breast and Ovarian Cancer Risk and the Likelihood of Carrying Genetic Pathogenic Variants. Cancer Epidemiology Biomarkers and Prevention, 2021, 30, 469-473.	2.5	98

#	ARTICLE	IF	CITATIONS
19	Cancer Risks Associated With *BRCA1* and *BRCA2* Pathogenic Variants. Journal of Clinical Oncology, 2022, 40, 1529-1541.	1.6	90
20	Incorporating truncating variants in PALB2, CHEK2, and ATM into the BOADICEA breast cancer risk model. Genetics in Medicine, 2016, 18, 1190-1198.	2.4	80
21	A risk prediction algorithm for ovarian cancer incorporating *BRCA1, BRCA2*, common alleles and other familial effects. Journal of Medical Genetics, 2015, 52, 465-475.	3.2	52
22	Validation of the BOADICEA model and a 313-variant polygenic risk score for breast cancer risk prediction in a Dutch prospective cohort. Genetics in Medicine, 2020, 22, 1803-1811.	2.4	49
23	Comparative validation of the BOADICEA and Tyrer-Cuzick breast cancer risk models incorporating classical risk factors and polygenic risk in a population-based prospective cohort of women of European ancestry. Breast Cancer Research, 2021, 23, 22.	5.0	49
24	DNA Glycosylases Involved in Base Excision Repair May Be Associated with Cancer Risk in BRCA1 and BRCA2 Mutation Carriers. PLoS Genetics, 2014, 10, e1004256.	3.5	47
25	Evaluating clinician acceptability of the prototype CanRisk tool for predicting risk of breast and ovarian cancer: A multi-methods study. PLoS ONE, 2020, 15, e0229999.	2.5	40
26	Evaluation of polygenic risk scores for ovarian cancer risk prediction in a prospective cohort study. Journal of Medical Genetics, 2018, 55, 546-554.	3.2	38
27	Comprehensive epithelial tubo-ovarian cancer risk prediction model incorporating genetic and epidemiological risk factors. Journal of Medical Genetics, 2022, 59, 632-643.	3.2	33
28	Homeobox B13 G84E Mutation and Prostate Cancer Risk. European Urology, 2019, 75, 834-845.	1.9	28
29	An original phylogenetic approach identified mitochondrial haplogroup T1a1 as inversely associated with breast cancer risk in BRCA2 mutation carriers. Breast Cancer Research, 2015, 17, 61.	5.0	26
30	Polygenic risk score is associated with increased disease risk in 52 Finnish breast cancer families. Breast Cancer Research and Treatment, 2016, 158, 463-469.	2.5	24
31	Candidate Genetic Modifiers for Breast and Ovarian Cancer Risk in *BRCA1* and *BRCA2* Mutation Carriers. Cancer Epidemiology Biomarkers and Prevention, 2015, 24, 308-316.	2.5	22
32	Performance of Breast Cancer Polygenic Risk Scores in 760 Female *CHEK2* Germline Mutation Carriers. Journal of the National Cancer Institute, 2021, 113, 893-899.	6.3	21
33	Population Study of Ovarian Cancer Risk Prediction for Targeted Screening and Prevention. Cancers, 2020, 12, 1241.	3.7	19
34	Prospective Evaluation of the Addition of Polygenic Risk Scores to Breast Cancer Risk Models. JNCI Cancer Spectrum, 2021, 5, pkab021.	2.9	19
35	Predicting the Likelihood of Carrying a *BRCA1* or *BRCA2* Mutation in Asian Patients With Breast Cancer. Journal of Clinical Oncology, 2022, 40, 1542-1551.	1.6	14
36	pedigreejs: a web-based graphical pedigree editor. Bioinformatics, 2018, 34, 1069-1071.	4.1	9

#	Article	IF	Citations
37	Potential of polygenic risk scores for improving population estimates of women's breast cancer genetic risks. Genetics in Medicine, 2021, 23, 2114-2121.	2.4	9
38	Should Age-Dependent Absolute Risk Thresholds Be Used for Risk Stratification in Risk-Stratified Breast Cancer Screening?. Journal of Personalized Medicine, 2021, 11, 916.	2.5	8
39	Prospective Evaluation over 15 Years of Six Breast Cancer Risk Models. Cancers, 2021, 13, 5194.	3.7	7
40	Profile study: Genetic prostate cancer risk stratification for targeted screening.. Journal of Clinical Oncology, 2013, 31, 5054-5054.	1.6	0
41	The PROFILE feasibility study: Genetic prostate cancer risk stratification for targeted screening.. Journal of Clinical Oncology, 2014, 32, 22-22.	1.6	0
42	Title is missing!. , 2020, 15, e0229999.		0
43	Title is missing!. , 2020, 15, e0229999.		0
44	Title is missing!. , 2020, 15, e0229999.		0
45	Title is missing!. , 2020, 15, e0229999.		0